Literature DB >> 30255250

Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Ijin Joo1,2, Jeong Min Lee3,4,5, Dong Ho Lee1,2, Ju Hyeon Jeon6, Joon Koo Han1,2,7.   

Abstract

OBJECTIVES: To validate new diagnostic criteria for hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced MR imaging (Gd-EOB-MRI) using hypointensity on the hepatobiliary phase (HBP) as an alternative to washout in combination with ancillary features.
METHODS: This retrospective study included 288 patients at high risk for HCC with 387 nodules (HCCs, n=292; non-HCCs, n=95) showing arterial phase hyper-enhancement (APHE) ≥1 cm on Gd-EOB-MRI. Imaging diagnoses of HCCs were made using different criteria: APHE plus hypointensity on the portal venous phase (PVP) (criterion 1), APHE plus hypointensity on the PVP and/or transitional phase (TP) (criterion 2), APHE plus hypointensity on the PVP and/or TP and/or HBP (criterion 3), and criterion 3 plus non-LR-1/2/M according to the Liver Imaging Reporting and Data System (LI-RADS) v2017 considering ancillary features (criterion 4). Sensitivities and specificities of those criteria were compared using McNemar's test.
RESULTS: Among diagnostic criteria for HCCs, criteria 3 and 4 showed significantly higher sensitivities (93.8% and 92.5%, respectively) than criteria 1 and 2 (70.9% and 86.6%, respectively) (p values <0.001). The specificity of criterion 4 (87.4%) was shown to be significantly higher than that of criterion 3 (48.4%, p<0.001), albeit comparable to criterion 2 (86.3%, p>0.999) and significantly lower than criterion 1 (97.9%, p=0.002).
CONCLUSIONS: In the non-invasive diagnosis of HCCs on Gd-EOB-MRI, HBP hypointensity may be used as an alternative to washout enabling a highly sensitive diagnosis with little loss in specificity if it is used after excluding nodules considered to be benignities or non-HCC malignancies based on characteristic imaging features. KEY POINTS: • Gd-EOB-MRI enhancement and ancillary features can be used to diagnose HCC. • Exclusion of LR-1/2/M improves specificity when HBP hypointensity is used.

Entities:  

Keywords:  Carcinoma, hepatocellular; Liver; Magnetic resonance imaging; Practice guideline

Mesh:

Substances:

Year:  2018        PMID: 30255250     DOI: 10.1007/s00330-018-5727-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  37 in total

Review 1.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 2.  Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Lewis R Roberts; Claude B Sirlin; Feras Zaiem; Jehad Almasri; Larry J Prokop; Julie K Heimbach; M Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2017-11-29       Impact factor: 17.425

3.  Global trends and predictions in hepatocellular carcinoma mortality.

Authors:  Paola Bertuccio; Federica Turati; Greta Carioli; Teresa Rodriguez; Carlo La Vecchia; Matteo Malvezzi; Eva Negri
Journal:  J Hepatol       Date:  2017-03-21       Impact factor: 25.083

Review 4.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

5.  Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.

Authors:  Soon Sun Kim; Jae Chul Hwang; Sun Gyo Lim; Seon Joo Ahn; Jae Youn Cheong; Sung Won Cho
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

6.  Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.

Authors:  Sang Hyun Choi; Jae Ho Byun; So Yeon Kim; So Jung Lee; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  Invest Radiol       Date:  2016-08       Impact factor: 6.016

7.  Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Xiang Li; Chenxia Li; Rong Wang; Juan Ren; Jian Yang; Yuelang Zhang
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

Review 8.  Hepatocellular carcinoma: a review.

Authors:  Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour
Journal:  J Hepatocell Carcinoma       Date:  2016-10-05

Review 9.  Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.

Authors: 
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

Review 10.  Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging and Multidetector-Row Computed Tomography for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Feng Ye; Jun Liu; Han Ouyang
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more
  21 in total

1.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.

Authors:  Jingbiao Chen; Sichi Kuang; Yao Zhang; Wenjie Tang; Sidong Xie; Linqi Zhang; Dailin Rong; Bingjun He; Ying Deng; Yuanqiang Xiao; Wenqi Shi; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-10-11

2.  Imaging of hepatocellular carcinoma: a pilot international survey.

Authors:  An Tang; Karma Abukasm; Guilherme Moura Cunha; Bin Song; Jin Wang; Mathilde Wagner; Christoph F Dietrich; Giuseppe Brancatelli; Kazuhiko Ueda; Jin-Young Choi; Diego Aguirre; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2021-01

Review 3.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

4.  A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma.

Authors:  Yi Wei; Zheng Ye; Yuan Yuan; Zixing Huang; Xiaocheng Wei; Tong Zhang; Shang Wan; Hehan Tang; Xiaopeng He; Bin Song
Journal:  Liver Cancer       Date:  2020-04-14       Impact factor: 11.740

5.  Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Authors:  Jielin Pan; Wenjuan Li; Lingjing Gu; Chaoran Liu; Ke Zhang; Guobin Hong
Journal:  Eur Radiol       Date:  2022-05-17       Impact factor: 5.315

6.  Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?

Authors:  Sidong Xie; Yao Zhang; Jingbiao Chen; Ting Jiang; Weimin Liu; Dailin Rong; Lin Sun; Linqi Zhang; Bingjun He; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2021-11-13

7.  Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.

Authors:  Sang Min Lee; Jeong Min Lee; Su Joa Ahn; Hyo Jin Kang; Hyun Kyung Yang; Jeong Hee Yoon
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

8.  Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined?

Authors:  Hyo-Jin Kang; Jung Hoon Kim; Jeongin Yoo; Joon Koo Han
Journal:  Ultrasonography       Date:  2021-12-17

Review 9.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

10.  Utility of Stack-of-stars Acquisition for Hepatobiliary Phase Imaging without Breath-holding.

Authors:  Shintaro Ichikawa; Utaroh Motosugi; Marie-Luise Kromrey; Daiki Tamada; Tetsuya Wakayama; Kang Wang; Ty A Cashen; Ali Ersoz; Hiroshi Onishi
Journal:  Magn Reson Med Sci       Date:  2019-05-07       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.